SBT-777101 is under clinical development by Sonoma Biotherapeutics and currently in Phase I for Rheumatoid Arthritis. According to GlobalData, Phase I drugs for Rheumatoid Arthritis have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SBT-777101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SBT-777101 is under development for the treatment of rheumatoid arthritis and hidradenitis suppurativa (HS). The drug candidate comprises of CAR-T regulatory cells (CAR Tregs) and is developed based on next generation genome editing and target-specific cell therapy.
Sonoma Biotherapeutics overview
Sonoma Biotherapeutics (Sonoma) is a biotechnology company that includes development of adoptive treg therapy cells for autoimmune and degenerative diseases. It is investing in its pipeline products which include SBT-77-7101, SBT-77-7200 Series, and SBT-11-5301 for the discovery of drugs targeted for the treatment of autoimmune and inflammatory diseases. The company leverages its regulatory T cells (Treg cells) which facilitate engineering and genetic reprogramming to suppress autoimmune diseases and maintain immune homeostasis. Its key funding partners include 8VC, Alexandria Venture Investments, Ally Bridge Group, and Arrowmark Partners, among others. Sonoma is headquartered in South San Francisco, California, United States.
For a complete picture of SBT-777101’s drug-specific PTSR and LoA scores, buy the report here.